Core Insights - ANI Pharmaceuticals, Inc. presented new preclinical data on Purified Cortrophin Gel at the EULAR 2025 Congress, demonstrating its efficacy in a murine model of collagen-induced arthritis [1][5] Group 1: Research Findings - In a preclinical model, repository corticotrophin injection (RCI) significantly reduced joint swelling and inflammatory cytokine response in mice without causing additional bone turnover, with the most pronounced effect observed at a dosage of 400 U/kg [2] - RCI treatment showed a dose-dependent effect on attenuating clinical scores and joint swelling compared to vehicle control, indicating its potential as a therapeutic option [2] Group 2: Research Leadership - The research was led by prominent figures in the field, including Maripat Corr, MD, and Nancy Lane, MD, from the University of California [3] Group 3: Company Commitment - ANI Pharmaceuticals emphasized its commitment to scientific and clinical research, collaborating with leading scientists to enhance understanding of its products and improve patient outcomes [4]
ANI Pharmaceuticals Announces Presentation of New Preclinical Data